ZA979236B - The preparation and use of ß-sulfonamido hydroxamic acids as matrix metalloproteinase and tace inhibitors. - Google Patents

The preparation and use of ß-sulfonamido hydroxamic acids as matrix metalloproteinase and tace inhibitors.

Info

Publication number: ZA979236B
Authority: ZA; South Africa
Prior art keywords: preparation; matrix metalloproteinase; hydroxamic acids; tace inhibitors; sulfonamido
Prior art date: 1996-10-16

Application number

ZA9709236A

Other languages

English (en)

Inventor

Jeremy Ian Levin

Arie Zask

Yansong Gu

Original Assignee

American Cyanamid Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-10-16

Filing date

1997-10-15

Publication date

1999-07-15

1997-10-15 Application filed by American Cyanamid Co filed Critical American Cyanamid Co

1999-07-15 Publication of ZA979236B publication Critical patent/ZA979236B/xx

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated

ZA9709236A 1996-10-16 1997-10-15 The preparation and use of ß-sulfonamido hydroxamic acids as matrix metalloproteinase and tace inhibitors. ZA979236B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US72935996A	1996-10-16	1996-10-16

Publications (1)

Publication Number	Publication Date
ZA979236B true ZA979236B (en)	1999-07-15

Family

ID=24930685

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA9709236A ZA979236B (en)	1996-10-16	1997-10-15	The preparation and use of ß-sulfonamido hydroxamic acids as matrix metalloproteinase and tace inhibitors.

Country Status (18)

Country	Link
EP (1)	EP0934259B1 (xx)
JP (1)	JP2001502326A (xx)
KR (1)	KR20000049198A (xx)
CN (1)	CN1105101C (xx)
AR (1)	AR008676A1 (xx)
AT (1)	ATE224364T1 (xx)
AU (1)	AU736134B2 (xx)
BR (1)	BR9712524A (xx)
CA (1)	CA2268895A1 (xx)
DE (1)	DE69715647T2 (xx)
DK (1)	DK0934259T3 (xx)
ES (1)	ES2184069T3 (xx)
HK (1)	HK1020720A1 (xx)
IL (1)	IL129149A (xx)
NZ (1)	NZ335053A (xx)
PT (1)	PT934259E (xx)
WO (1)	WO1998016506A1 (xx)
ZA (1)	ZA979236B (xx)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT952148E (pt) *	1998-04-10	2004-09-30	Pfizer Prod Inc	Derivados de acido ciclobutil-ariloxiarilsulfonilamino-hidroxamico
EP1087937A1 (en)	1998-06-17	2001-04-04	Du Pont Pharmaceuticals Company	Cyclic hydroxamic acids as metalloproteinase inhibitors
US6326516B1 (en)	1999-01-27	2001-12-04	American Cyanamid Company	Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
US6340691B1 (en)	1999-01-27	2002-01-22	American Cyanamid Company	Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
BR0007784A (pt)	1999-01-27	2002-02-05	American Cyanamid Co	Composto, método para inibir mudanças patológicas mediadas pela enzima que converte o tnf-alfa (tace) em um mamìfero, composição farmacêutica, e, processo para preparar um composto
US6200996B1 (en)	1999-01-27	2001-03-13	American Cyanamid Company	Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
US6753337B2 (en)	1999-01-27	2004-06-22	Wyeth Holdings Corporation	Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6946473B2 (en)	1999-01-27	2005-09-20	Wyeth Holdings Corporation	Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
US6277885B1 (en)	1999-01-27	2001-08-21	American Cyanamid Company	Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6225311B1 (en)	1999-01-27	2001-05-01	American Cyanamid Company	Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6313123B1 (en)	1999-01-27	2001-11-06	American Cyanamid Company	Acetylenic sulfonamide thiol tace inhibitors
US6762178B2 (en)	1999-01-27	2004-07-13	Wyeth Holdings Corporation	Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
WO2000046189A1 (fr) *	1999-02-02	2000-08-10	Shionogi & Co., Ltd.	Derives de la sulfonamide a structures cycliques
KR100780989B1 (ko) *	2000-05-23	2007-11-29	오스모닉스 인코포레이티드	개질된 술폰아미드 중합체
JP2005507937A (ja)	2001-11-01	2005-03-24	ワイス・ホールディングズ・コーポレイション	マトリックスメタロプロテイナーゼおよびｔａｃｅ阻害剤としてのアレンアリールスルホンアミドヒドロキサム酸
US7491718B2 (en)	2002-10-08	2009-02-17	Abbott Laboratories	Sulfonamides having antiangiogenic and anticancer activity
US20040157836A1 (en) *	2002-10-08	2004-08-12	Comess Kenneth M.	Sulfonamides having antiangiogenic and anticancer activity
US7199155B2 (en)	2002-12-23	2007-04-03	Wyeth Holdings Corporation	Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
ATE449760T1 (de)	2004-03-22	2009-12-15	Southern Res Inst	Nichtpeptidinhibitoren von matrixmetalloproteinasen
FR2947268B1 (fr)	2009-06-30	2011-08-26	Galderma Res & Dev	Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
FR2947270B1 (fr)	2009-06-30	2011-08-26	Galderma Res & Dev	Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
US20140275108A1 (en)	2013-03-15	2014-09-18	Galderma Research & Development	Novel benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics
IL237852A0 (en)	2015-03-19	2016-03-24	Yeda Res & Dev	Antibodies against amphigoline, medical preparations containing them and their use
WO2017117130A1 (en)	2015-12-28	2017-07-06	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells
EP3199534B1 (en)	2016-02-01	2018-09-05	Galderma Research & Development	Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine and cosmetics
BR112021006407A8 (pt)	2018-10-04	2022-12-06	Inst Nat Sante Rech Med	uso de inibidores do egfr para ceratodermas

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5455258A (en) *	1993-01-06	1995-10-03	Ciba-Geigy Corporation	Arylsulfonamido-substituted hydroxamic acids
WO1994022309A1 (en) *	1993-04-07	1994-10-13	Glycomed Incorporated	Synthetic matrix metalloprotease inhibitors and uses thereof
US5672598A (en) *	1995-03-21	1997-09-30	The Procter & Gamble Company	Lactam-containing hydroxamic acids

1997
- 1997-10-08 JP JP10518424A patent/JP2001502326A/ja not_active Ceased
- 1997-10-08 DE DE69715647T patent/DE69715647T2/de not_active Expired - Fee Related
- 1997-10-08 IL IL12914997A patent/IL129149A/xx not_active IP Right Cessation
- 1997-10-08 DK DK97912674T patent/DK0934259T3/da active
- 1997-10-08 BR BR9712524-5A patent/BR9712524A/pt not_active Application Discontinuation
- 1997-10-08 NZ NZ335053A patent/NZ335053A/xx unknown
- 1997-10-08 KR KR1019990703296A patent/KR20000049198A/ko active IP Right Grant
- 1997-10-08 CN CN97180606A patent/CN1105101C/zh not_active Expired - Fee Related
- 1997-10-08 AU AU49790/97A patent/AU736134B2/en not_active Ceased
- 1997-10-08 PT PT97912674T patent/PT934259E/pt unknown
- 1997-10-08 ES ES97912674T patent/ES2184069T3/es not_active Expired - Lifetime
- 1997-10-08 AT AT97912674T patent/ATE224364T1/de not_active IP Right Cessation
- 1997-10-08 WO PCT/US1997/018170 patent/WO1998016506A1/en active IP Right Grant
- 1997-10-08 CA CA002268895A patent/CA2268895A1/en not_active Abandoned
- 1997-10-08 EP EP97912674A patent/EP0934259B1/en not_active Expired - Lifetime
- 1997-10-15 ZA ZA9709236A patent/ZA979236B/xx unknown
- 1997-10-15 AR ARP970104748A patent/AR008676A1/es not_active Application Discontinuation
1999
- 1999-12-11 HK HK99105839A patent/HK1020720A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
ATE224364T1 (de)	2002-10-15
EP0934259B1 (en)	2002-09-18
WO1998016506A1 (en)	1998-04-23
CN1105101C (zh)	2003-04-09
AU736134B2 (en)	2001-07-26
IL129149A0 (en)	2000-02-17
KR20000049198A (ko)	2000-07-25
NZ335053A (en)	2000-10-27
DE69715647D1 (en)	2002-10-24
DE69715647T2 (de)	2003-02-20
DK0934259T3 (da)	2003-01-27
ES2184069T3 (es)	2003-04-01
JP2001502326A (ja)	2001-02-20
CN1240424A (zh)	2000-01-05
AU4979097A (en)	1998-05-11
IL129149A (en)	2003-10-31
BR9712524A (pt)	1999-10-19
EP0934259A1 (en)	1999-08-11
PT934259E (pt)	2003-01-31
AR008676A1 (es)	2000-02-09
CA2268895A1 (en)	1998-04-23
HK1020720A1 (en)	2000-05-19

Publication	Publication Date	Title
ZA979238B (en)	1999-07-15	The preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors.
ZA979236B (en)	1999-07-15	The preparation and use of ß-sulfonamido hydroxamic acids as matrix metalloproteinase and tace inhibitors.
ZA979233B (en)	1999-04-15	The preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
ZA979235B (en)	1999-04-15	The preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
HK1011536A1 (en)	1999-07-16	Alpha-substituted arylsulphonamido hydroxamic acids as tnf-alpha and matrix metalloproteinase inhibitors
HUP0101613A3 (en)	2003-01-28	Metalloprotease inhibitor (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides and medicaments containing the same
AU4422096A (en)	1996-07-24	Hydroxamic acid-containing inhibitors of matrix metalloproteases
ZA981532B (en)	1999-08-24	Reverse hydroxamate derivatives as matrix metalloprotease inhibitors, metalloprotease inhibitors, and TNF alpha inhibitors.
GB9401129D0 (en)	1994-03-16	Hydroxamic acid derivatives as metalloproteinase inhibitors
AU9021498A (en)	1999-03-08	Novel inhibitors of aggrecanase and matrix metalloproteinases for the treatment of arthritis
AU5556396A (en)	1996-11-07	Hydroxamic and carboxylic acids as metalloprotease inhibitor s
AU3107795A (en)	1996-03-07	Inhibitors of the benzamidine type
IL127262A0 (en)	1999-09-22	Matrix metalloproteinase inhibitors
AU2735995A (en)	1996-01-04	Hydroxylamine derivatives and their use as metalloproteinase inhibiting agents
HUP9904165A3 (en)	2002-01-28	3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase and use thereof
IL115995A0 (en)	1996-01-31	Substituted 4-biarylbutyric or 5-biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors
AU7688998A (en)	1998-12-11	Use of metalloproteinase inhibitors in the treatment and prevention of pulmonaryemphysema
GB9707540D0 (en)	1997-06-04	Phenolic acid esterase and use thereof
AU5226798A (en)	1998-06-29	Use of paracetamol as depigmenting agent
GB9502858D0 (en)	1995-04-05	Novel use of matrix metalloproteinase inhibitors
AU7066398A (en)	1998-11-13	Novel use of matrix metalloproteinase inhibitors
ZA964660B (en)	1998-02-25	Hydroxamic and carbocyclic acids as metalloprotease inhibitors.
ZA964668B (en)	1998-02-25	Hydroxamic acid and amino-carboxylate compounds as metalloprotease and TNF inhibitors.
AU1836800A (en)	2000-07-24	Amidomalonamides and their use as inhibitors of matrix metalloproteinase
SI0873312T1 (en)	2002-12-31	Alpha-substituted arylsulphonamido hydroxamic acids as tnf-alpha and matrix metalloproteinase inhibitors